Ceftazidime: Third-Generation Cephalosporin Targeting Pseudomonas aeruginosa

Executive Summary: Ceftazidime is a third-generation cephalosporin with potent activity against Gram-negative bacteria, notably Pseudomonas aeruginosa, due to high β-lactamase resistance (APExBIO). Its mechanism is bactericidal, inhibiting cell wall synthesis in susceptible strains (tcephydrochloride.com). Ceftazidime is less active against Staphylococcus aureus than earlier cephalosporins. Clinical and research use centers on pneumonia and bronchitis caused by multidrug-resistant organisms (gestrinonesource.com). β-lactamase-producing Enterobacteriaceae are a key target, with resistance mechanisms and clinical breakpoints actively studied (Chen et al., BMC Microbiology 2025).

Biological Rationale

Ceftazidime (C22H22N6O7S2; MW 546.58) is a synthetic, third-generation cephalosporin antibiotic developed to address emerging resistance in Gram-negative bacteria. It is designed to resist hydrolysis by common β-lactamases, which are enzymes responsible for antibiotic inactivation in Enterobacteriaceae and Pseudomonas species (APExBIO). This property extends its spectrum and efficacy where first- and second-generation cephalosporins are ineffective. Ceftazidime exhibits high affinity for penicillin-binding proteins (PBPs), especially PBP3, crucial for cell wall crosslinking in Gram-negative rods. The compound is a solid, highly soluble in DMSO (≥21.25 mg/mL), but insoluble in ethanol and water. Its storage at –20°C preserves stability, minimizing degradation before use in experimental or clinical settings.

Mechanism of Action of Ceftazidime

Ceftazidime exerts its bactericidal effect by binding PBPs involved in the final transpeptidation step of peptidoglycan synthesis, thereby inhibiting bacterial cell wall formation (GestrinoneSource). This results in cell lysis and death in susceptible bacteria. The β-lactam ring is the pharmacophore responsible for this action, and ceftazidime's resistance to hydrolysis by β-lactamases allows it to remain active against many resistant clinical isolates, including Pseudomonas aeruginosa and β-lactamase-producing Enterobacteriaceae. However, its activity against Gram-positive cocci, such as Staphylococcus aureus, is reduced compared to earlier cephalosporins. The compound is not active against most anaerobes and is ineffective against bacteria lacking a classic cell wall (e.g., Mycoplasma).

Evidence & Benchmarks

• Ceftazidime demonstrates potent in vitro activity against Pseudomonas aeruginosa, outperforming other cephalosporins of its class (APExBIO product page).
• It is highly resistant to hydrolysis by β-lactamases produced by Enterobacteriaceae, enabling efficacy where many β-lactam antibiotics fail (Tcephydrochloride.com article).
• Clinical isolates of carbapenem-resistant Enterobacter cloacae frequently carry β-lactamase-encoding genes (blaNDM-1, blaIMP, blaKPC-2), many of which confer high ceftazidime resistance, especially when combined with avibactam (Chen et al., BMC Microbiology 2025).
• Recommended dosing for severe infections (e.g., pneumonia, bronchitis) is 3–6 g/day in 2–4 divided doses in adult patients, with adjustments for renal impairment (APExBIO).
• Resistance emergence in Pseudomonas and Enterobacteriaceae is closely tied to horizontal gene transfer and mobile genetic elements, highlighting the need for stewardship and surveillance (Chen et al., BMC Microbiology 2025).

This article updates and extends the summary provided in Tcephydrochloride.com by detailing specific resistance mechanisms in clinical settings, and clarifies the spectrum of activity relative to the overview at GestrinoneSource.

Applications, Limits & Misconceptions

Ceftazidime is indicated for research and clinical management of infections caused by susceptible Gram-negative aerobic bacteria, including hospital-acquired pneumonia, bronchitis, urinary tract infections, and sepsis. Its use is especially critical in treating multidrug-resistant Pseudomonas aeruginosa, a frequent cause of ventilator-associated pneumonia (APExBIO). The compound is also applied in laboratory studies to characterize resistance phenotypes and screen β-lactamase inhibitors.

Common Pitfalls or Misconceptions

• Ceftazidime is not broadly effective against Gram-positive cocci; it is less active than earlier cephalosporins against Staphylococcus aureus (APExBIO).
• It does not cover most anaerobes or atypical bacteria (e.g., Mycoplasma, Chlamydia).
• Resistance may develop through mobile genetic elements, particularly in carbapenemase-producing Enterobacteriaceae (Chen et al., BMC Microbiology 2025).
• Stock solutions are unstable at room temperature and must be stored at –20°C or below to prevent degradation (APExBIO).
• It should not be considered effective against all multidrug-resistant organisms, as some strains may possess additional resistance determinants.

Workflow Integration & Parameters

For laboratory research, ceftazidime is supplied as a solid by APExBIO (SKU: B3539). Dissolve at ≥21.25 mg/mL in DMSO for stock solutions; avoid ethanol or water due to insolubility. Store stock solutions at or below –20°C and use promptly. For in vitro susceptibility testing, follow Clinical and Laboratory Standards Institute (CLSI) protocols, with broth microdilution as the standard method. In clinical research, dosages should be adjusted for renal function and divided into 2–4 daily administrations. Monitor for resistance emergence, especially in studies involving Pseudomonas or Enterobacteriaceae with known β-lactamase or carbapenemase genes.

Conclusion & Outlook

Ceftazidime remains a pivotal agent in the fight against Gram-negative bacterial infections, notably those caused by Pseudomonas aeruginosa and β-lactamase-producing Enterobacteriaceae. Ongoing surveillance of resistance mechanisms, such as the spread of carbapenemase-encoding genes, is essential. The robust β-lactamase resistance profile of ceftazidime supports its continued use in both research and clinical settings. For further details and procurement, refer to the APExBIO Ceftazidime product page.